These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. Jaksic W; Trudel S; Chang H; Trieu Y; Qi X; Mikhael J; Reece D; Chen C; Stewart AK J Clin Oncol; 2005 Oct; 23(28):7069-73. PubMed ID: 16129840 [TBL] [Abstract][Full Text] [Related]
10. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605 [TBL] [Abstract][Full Text] [Related]
11. Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Bonnet J; Alexanian R; Salmon S; Bottomley R; Amare M; Haut A; Dixon D Cancer Treat Rep; 1982 Jun; 66(6):1267-71. PubMed ID: 7044534 [TBL] [Abstract][Full Text] [Related]
12. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Bonnet JD; Alexanian R; Salmon SE; Haut A; Dixon DO Cancer Treat Rep; 1984 Mar; 68(3):481-5. PubMed ID: 6200220 [TBL] [Abstract][Full Text] [Related]
13. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma]. Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189 [TBL] [Abstract][Full Text] [Related]
14. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
15. HyperCVAD for VAD-resistant multiple myeloma. Dimopoulos MA; Weber D; Kantarjian H; Delasalle KB; Alexanian R Am J Hematol; 1996 Jun; 52(2):77-81. PubMed ID: 8638645 [TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E; Kilpi H Eur J Haematol; 1989 Oct; 43(4):328-31. PubMed ID: 2583258 [TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol). Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205 [TBL] [Abstract][Full Text] [Related]
18. Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie B; Smith L; Alexanian R N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971 [TBL] [Abstract][Full Text] [Related]
19. [Plasmocytic pleural effusion disclosing multiple myeloma]. Elloumi M; Frikha M; Masmoudi H; Mseddi S; Ben Ayed M; Bouaziz M; Makni F; Souissi T Rev Mal Respir; 2000 Apr; 17(2):495-7. PubMed ID: 10859769 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma. Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]